硼替佐米治疗复发多发性骨髓瘤患者相关的血栓性微血管病
Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma.
作者信息
Salmenniemi Urpu, Remes Kari
机构信息
Turku University Hospital, Department of Medicine, Finland.
出版信息
Hematol Rep. 2012 May 10;4(2):e13. doi: 10.4081/hr.2012.e13. Epub 2012 Jun 29.
Abstract
Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS) describe microvascular occlusive disorders characterized by thrombocytopenia due to increased platelet aggregation and fragmentation hemolysis. We report here what to our knowledge is the second case of TTP/HUS associated with bortezomib treatment.
摘要
血栓性血小板减少性紫癜（TTP）和溶血性尿毒症综合征（HUS）是微血管闭塞性疾病，其特征为血小板聚集增加导致血小板减少以及碎裂性溶血。我们在此报告据我们所知第二例与硼替佐米治疗相关的TTP/HUS病例。
相似文献
1
Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma.硼替佐米治疗复发多发性骨髓瘤患者相关的血栓性微血管病
Hematol Rep. 2012 May 10;4(2):e13. doi: 10.4081/hr.2012.e13. Epub 2012 Jun 29.
2
Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.血栓性血小板减少性紫癜和溶血性尿毒症综合征的发病机制、诊断及治疗进展
Thromb Res. 2006;118(2):177-84. doi: 10.1016/j.thromres.2005.07.013. Epub 2005 Aug 29.
3
Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?恶性高血压与溶血尿毒综合征（HUS）/血栓性血小板减少性紫癜（TTP）中的血栓性微血管病：我们能将两者区分开吗？
Hypertens Res. 2005 Jan;28(1):89-95. doi: 10.1291/hypres.28.89.
4
Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?血栓性血小板减少性紫癜和溶血尿毒综合征是否存在共同的病理生理学机制？
J Am Soc Nephrol. 2007 Sep;18(9):2457-60. doi: 10.1681/ASN.2007010062. Epub 2007 Aug 8.
5
Recent advances in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的最新进展
Hematology Am Soc Hematol Educ Program. 2004:407-23. doi: 10.1182/asheducation-2004.1.407.
6
Syndromes of Thrombotic Microangiopathy.血栓性微血管病综合征。
Med Clin North Am. 2017 Mar;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010. Epub 2016 Dec 27.
7
8
Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).血栓性血小板减少性紫癜/溶血性尿毒症综合征（TTP/HUS）中的两种新型ADAMTS13基因突变。
Kidney Int. 2004 Sep;66(3):955-8. doi: 10.1111/j.1523-1755.2004.00841.x.
9
Thrombotic microangiopathy in cancer.癌症相关性血栓性微血管病。
Thromb Res. 2018 Apr;164 Suppl 1:S103-S105. doi: 10.1016/j.thromres.2018.01.014. Epub 2018 Jan 9.
10
Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies.血栓性血小板减少性紫癜（TTP）和其他血栓性微血管病。
Best Pract Res Clin Haematol. 2009 Dec;22(4):567-76. doi: 10.1016/j.beha.2009.07.004.
引用本文的文献
1
Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China.依库珠单抗治疗非典型溶血性尿毒症综合征的真实世界疗效：一项来自中国西部的回顾性研究。
Front Endocrinol (Lausanne). 2025 Jun 27;16:1568082. doi: 10.3389/fendo.2025.1568082. eCollection 2025.
2
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.蛋白酶体抑制剂相关血栓性微血管病：一项真实世界回顾性和药物警戒数据库分析。
Support Care Cancer. 2025 Feb 13;33(3):184. doi: 10.1007/s00520-025-09219-w.
3
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.蛋白酶体抑制剂相关的血栓性微血管病：系统全面的综述。
Blood Cancer J. 2024 Nov 7;14(1):196. doi: 10.1038/s41408-024-01182-9.
4
Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy.硼替佐米相关血栓性微血管病的独特表现对治疗性血浆置换和依库珠单抗治疗有反应
Hematol Rep. 2022 Apr 5;14(2):119-125. doi: 10.3390/hematolrep14020018.
5
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.在CARDAMON研究中，接受卡非佐米、环磷酰胺和地塞米松治疗的未治疗骨髓瘤患者中的血栓性微血管病。
Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1.
6
Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.蛋白酶体抑制剂治疗引发冒烟型骨髓瘤患者肾肺血栓性微血管病：一例肾活检及尸检病例报告
Medicine (Baltimore). 2019 Sep;98(39):e17148. doi: 10.1097/MD.0000000000017148.
7
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.多发性骨髓瘤患者使用硼替佐米引发的肾血栓性微血管病
Case Rep Hematol. 2016;2016:6020691. doi: 10.1155/2016/6020691. Epub 2016 May 16.
8
Thrombotic microangiopathy associated with proteasome inhibitors.与蛋白酶体抑制剂相关的血栓性微血管病
Clin Kidney J. 2015 Oct;8(5):632-6. doi: 10.1093/ckj/sfv059. Epub 2015 Jul 16.
9
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.一名多发性骨髓瘤患者使用卡非佐米后出现的肾血栓性微血管病和足细胞病
BMC Nephrol. 2014 Sep 30;15:156. doi: 10.1186/1471-2369-15-156.
本文引用的文献
1
A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura.一例表现为血栓性血小板减少性紫癜的播散性腺癌报告。
Hematol Rep. 2011 Aug 31;3(2):e14. doi: 10.4081/hr.2011.e14. Epub 2011 Oct 7.
2
TTP-HUS associated with sunitinib.与舒尼替尼相关的 TTP-HUS。
Cancer Res Treat. 2008 Dec;40(4):211-3. doi: 10.4143/crt.2008.40.4.211. Epub 2008 Dec 31.
3
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.一名多发性骨髓瘤患者在接受硼替佐米和地塞米松治疗后发生血栓性微血管病。
Int J Hematol. 2008 Sep;88(2):248-250. doi: 10.1007/s12185-008-0140-1. Epub 2008 Jul 19.
4
VEGF inhibition and renal thrombotic microangiopathy.血管内皮生长因子抑制与肾血栓性微血管病
N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.
5
Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.血栓性血小板减少性紫癜和溶血性尿毒症综合征的发病机制、诊断及治疗进展
Thromb Res. 2006;118(2):177-84. doi: 10.1016/j.thromres.2005.07.013. Epub 2005 Aug 29.
6
Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.药物性血栓性血小板减少性紫癜/溶血尿毒综合征：简要综述
Ther Apher Dial. 2004 Apr;8(2):102-11. doi: 10.1111/j.1526-0968.2003.00127.x.
7
NF-kappaB in cancer: from innocent bystander to major culprit.癌症中的核因子-κB：从无辜旁观者到主要元凶
Nat Rev Cancer. 2002 Apr;2(4):301-10. doi: 10.1038/nrc780.
Zotero 插件